Conexiant’s news site is now MDSpire News. Learn more
Advertisement
ESMO26: Antonio Giordano, MD, PhD, on FOURLIGHT
Antonio Gioradano, MD, presents efficacy and safety of atirmociclib + fulvestrant in HR+/HER2- advanced breast cancer after progressing on prior CDK4/6 inhibitor - data from phase 2 FOURLIGHT-1 study.
The presentation covers the efficacy and safety of atirmociclib plus fulvestrant in HR-positive/HER2-negative advanced breast cancer after progression on a prior CDK4/6 inhibitor.
Approach:
Study: Phase 2 FOURLIGHT-1 study.
Treatment: Atirmociclib plus fulvestrant.
Interpretation:
The provided context identifies the study and treatment but does not report efficacy or safety results.
Limitations:
No study results, participant details, or methods beyond the phase and treatment are provided.